Robert Doyle, the Jack and Laura H. Milton Professor and Dean's Professor of Chemistry at Syracuse University, was featured in a Bio IT World article detailing his lab’s work on a new class of weight-loss drugs that could revolutionize obesity treatment.

The article, titled “Quest is on for a ‘Super-Tolerable’ Weight-Loss Drug,” highlights Doyle’s efforts to develop a medication that avoids the common side effects associated with popular drugs like Ozempic and Zepbound. With nearly 70% of Americans classified as overweight or obese, Doyle’s research aims to address the limitations of current treatments that activate the GLP-1 pathway, often causing nausea, vomiting and other intolerable symptoms.

The ultimate goal, Doyle emphasized, is to produce a drug that is not only effective but “super-tolerable,” allowing patients to maintain a high quality of life while undergoing treatment.